First Time Loading...

ICON PLC
NASDAQ:ICLR

Watchlist Manager
ICON PLC Logo
ICON PLC
NASDAQ:ICLR
Watchlist
Price: 321.915 USD 2.82% Market Closed
Updated: Jul 27, 2024
Have any thoughts about
ICON PLC?
Write Note

Intrinsic Value

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. [ Read More ]

The intrinsic value of one ICLR stock under the Base Case scenario is 330.555 USD. Compared to the current market price of 321.915 USD, ICON PLC is Undervalued by 3%.

Key Points:
ICLR Intrinsic Value
Base Case
330.555 USD
Undervaluation 3%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ICON PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ICLR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ICON PLC

Current Assets 3.6B
Cash & Short-Term Investments 398m
Receivables 3B
Other Current Assets 149.1m
Non-Current Assets 13.5B
Long-Term Investments 51.2m
PP&E 512.9m
Intangibles 12.8B
Other Non-Current Assets 162m
Current Liabilities 2.9B
Accounts Payable 113.6m
Other Current Liabilities 2.8B
Non-Current Liabilities 4.7B
Long-Term Debt 3.4B
Other Non-Current Liabilities 1.2B
Efficiency

Earnings Waterfall
ICON PLC

Revenue
8.2B USD
Cost of Revenue
-5.8B USD
Gross Profit
2.4B USD
Operating Expenses
-1.3B USD
Operating Income
1.1B USD
Other Expenses
-417.2m USD
Net Income
683.2m USD

Free Cash Flow Analysis
ICON PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ICLR Profitability Score
Profitability Due Diligence

ICON PLC's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Free Cash Flow
Positive Gross Profit
Positive Revenue Growth Forecast
52/100
Profitability
Score

ICON PLC's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

ICLR Solvency Score
Solvency Due Diligence

ICON PLC's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
High Altman Z-Score
Short-Term Solvency
54/100
Solvency
Score

ICON PLC's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ICLR Price Targets Summary
ICON PLC

Wall Street analysts forecast ICLR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ICLR is 373.32 USD with a low forecast of 333.3 USD and a high forecast of 409.5 USD.

Lowest
Price Target
333.3 USD
4% Upside
Average
Price Target
373.32 USD
16% Upside
Highest
Price Target
409.5 USD
27% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ICLR?

Click here to dive deeper.

Competitive Landscape

Price Appreciation

ICLR Price
ICON PLC

1M 1M
+3%
6M 6M
+20%
1Y 1Y
+33%
3Y 3Y
+44%
5Y 5Y
+104%
10Y 10Y
+583%
Annual Price Range
321.915
52w Low
222.83
52w High
346.2
Price Metrics
Average Annual Return 10.02%
Standard Deviation of Annual Returns 36.33%
Max Drawdown -35%
Shares Statistics
Market Capitalization 26.6B USD
Shares Outstanding 82 777 296
Percentage of Shares Shorted 2.44%

ICLR Return Decomposition
Main factors of price return

What is price return decomposition?

ICLR News

Other Videos

Company Profile

ICON PLC Logo
ICON PLC

Country

Ireland

Industry

Life Sciences Tools & Services

Market Cap

26.6B USD

Dividend Yield

0%

Description

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Dublin, Dublin and currently employs 38,330 full-time employees. The firm is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. The firm specialises in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The company conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The firm offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.

Contact

DUBLIN
DUBLIN
South County Business Park, Dublin 18
+35312912000.0
http://www.iconplc.com/

IPO

1998-05-15

Employees

38 330

Officers

Founder & Independent Non-Executive Director
Dr. John Climax Ph.D.
Chief Financial Officer
Mr. Brendan Brennan
CEO & Director
Dr. Steven A. Cutler MBA, Ph.D.
Senior Vice President of Corporate & Commercial Finance
Jonathan Andrew Curtain
Chief Information Officer
Mr. Thomas N. O'Leary
Chief Administrative Officer, General Counsel & Company Secretary
Mr. Diarmaid Cunningham
Show More
Director of Corporate Communications
Ms. Niamh Murphy
Vice President of Marketing
Mr. David Green
Chief Human Resources Officer
Mr. Joe Cronin
President of Corporate Investments & Partnerships
Mr. Simon Holmes
Show Less

See Also

Discover More
What is the Intrinsic Value of one ICLR stock?

The intrinsic value of one ICLR stock under the Base Case scenario is 330.555 USD.

Is ICLR stock undervalued or overvalued?

Compared to the current market price of 321.915 USD, ICON PLC is Undervalued by 3%.